Latest From Advaxis Inc.
Public Company Edition: Jefferies report notes robust IPO market, but SVB Leerink predicts a financing slowdown. Also, Mirati raises cash for KRAS programs after Amgen's ASCO data and a strategic shift results in job cuts at ImmunoGen.
Troubled by a clinical hold for another program, Advaxis now regains all rights to ADXS-NEO, a personalized immunotherapy in Phase I for cervical and head-and-neck cancers.
It remains unclear what impact the consolidation within the drug-distribution sector may have on pricing. Pfizer partners with France’s Cytoo for its new gene therapy approach to DMD, while Gilead teams with Precision BioSciences for its goal to cure HBV.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Advaxis Inc.
- Senior Management
Kenneth Berlin, Pres. & CEO
Molly Henderson, EVP, CFO
Andrew A Gutierrez, MD, PhD, EVP, CMO
- Contact Info
Phone: (609) 452-9813
305 College Rd. East
Princeton, NJ 08540
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.